Search
Robenacoxib
go.drugbank.com/drugs/DB11455ExperimentalVet approvedRobenacoxib is a non-steroidal anti-inflammatory drug used in veterinary medicine for the relief of pain and inflammation in cats and dogs.
Pirlimycin
go.drugbank.com/drugs/DB11537ExperimentalVet approvedPirlimycin hydrochloride is an antibiotic belonging to the _lincosamide_ class. Often marketed as _Pirsue_, this drug is used to treat mastitis in cattle.
Anetumab ravtansine
go.drugbank.com/drugs/DB14809InvestigationalAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Osocimab
go.drugbank.com/drugs/DB14818InvestigationalOsocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
Selitrectinib
go.drugbank.com/drugs/DB14896InvestigationalSelitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).
5-methyl-2'-fluoroarauracil F-18
go.drugbank.com/drugs/DB14913Investigational5-methyl-2'-fluoroarauracil F-18 is under investigation in clinical trial NCT02809690 (18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer).
BMS-929075
go.drugbank.com/drugs/DB14950InvestigationalBMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).
Opicinumab
go.drugbank.com/drugs/DB14959InvestigationalOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
AOC 1001
go.drugbank.com/drugs/DB18620InvestigationalDelpacibart (AOC 1001) is being investigated in a global study for the treatment of Myotonic Dystrophy type 1 (DM1) in clinical trial NCT06411288
MBP134
go.drugbank.com/drugs/DB18686ExperimentalMBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).